comprehensive -WSS

comprehensive

author：fashion 2025-09-27 09:40:19 - browse：989

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Wegovy leads to weight loss. Can it treat depression, too?

hotspot

WSS

Thousands of Marines and sailors deploy to Middle East to deter Iran from seizing ships

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

In medicine, common shorthands can shortchange care

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

Bernie Sanders is gearing up to subpoena pharma CEOs

Bernie Sanders is gearing up to subpoena pharma CEOs

hotspot

comprehensive

leisure time

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The Affordable Care Act has saved billions in health care costs

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Arizona Democrat to raise extreme heat with Biden 1 year out from Senate primary

Bright Health sells Medicare Advantage business to Molina

More people are opting for early dinners since the pandemic, says OpenTable CEO Debby Soo

Jerome Adams on the need for new antivirals for Covid

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Affirmative action in medical school literally saved lives

Biogen walks away from Aduhelm, years after polarizing approval

Wikipedia

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Biogen walks away from Aduhelm, years after polarizing approval

Boston competes with Raleigh

Bursting ice dam in Alaska highlights risks of glacial flooding around the globe

More people are opting for early dinners since the pandemic, says OpenTable CEO Debby Soo

Health Care Service Corp to buy Cigna Medicare Advantage plans

hotspot

hotspot

entertainment

hotspot